A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)

Tudor-Eliade Ciuleanu,Galina Kurteva,J Ocvirk,S. Beslija,I. Koza,Demetris Papamichael,Damir Vrbanec,Thomas Brodowicz,W. Scheithauer,C. Zielinski

A randomized, open-label CECOG phase II study evaluating the efficacy and safety of FOLFOX6 + cetuximab versus FOLFIRI + cetuximab as first-line therapy in patients (pts) with metastatic colorectal cancer (mCRC)

2008

Tudor-Eliade Ciuleanu
Galina Kurteva
J Ocvirk
S. Beslija
I. Koza
Demetris Papamichael
Damir Vrbanec
Thomas Brodowicz
W. Scheithauer
C. Zielinski

4032 Background: FOLFOX6 and FOLFIRI are standard first-line regimens in mCRC. The monoclonal antibody cetuximab is active in combination with both regimens. This trial evaluated cetuximab+FOLFOX6 ...

Keywords:

Physical therapy
Cetuximab
FOLFIRI
Colorectal cancer
Phases of clinical research
Oncology
Cancer research
Internal medicine
Medicine
in patient
open label
first line therapy

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations